ArticleGeneral psychiatry2022
TNF-α, IL-6 and hsCRP in patients with melancholic, atypical and anxious depression: an antibody array analysis related to somatic symptoms.
Article in General psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03219008 (Multi-dimensional Diagnosis,Individualized Therapy,and Management Technique for Major Depressive Disorder), which is not on this map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Multi-dimensional Diagnosis,Individualized Therapy,and Management Technique for Major Depressive Disorder:Based on Clinical and Pathological Characteristics
Who cites it
15 citing papers in PubMed.
- Compound Ciwujia Granules Attenuate Stress-Induced Anxiety- and Depression-Like Behaviors via Inhibition of TNF-α-Associated Neuroinflammation in the dmPFC.CNS neuroscience & therapeutics · 2026Article
- Effect of postoperative esketamine on depression after pancreatoduodenectomy: a randomized controlled trial.Perioperative medicine (London, England) · 2026Article
- Lidocaine for Depressive Symptoms and Comorbid Pain: A Narrative Review of Mechanisms, Evidence, and Safety.Drug design, development and therapy · 2026Review
- The association between heart rate variability and inflammatory markers in first-episode depressed patients with different sleep quality.BMC psychiatry · 2025Article
- The Kynurenine Pathway in Gut Permeability and Inflammation.Inflammation · 2025Review
- Pathogenesis of HIV-associated depression: contributing factors and underlying mechanisms.Frontiers in psychiatry · 2025Review
- Gut-Brain Axis and Neuroinflammation: The Role of Gut Permeability and the Kynurenine Pathway in Neurological Disorders.Cellular and molecular neurobiology · 2024Review
- Inflammatory biomarkers in depression: scoping review.BJPsych open · 2024Article
- Systemic low-grade inflammation associated with specific depressive symptoms: insights from network analyses of five independent NHANES samples.General psychiatry · 2024Article
- Article
- Mental stress, atheroma, myocardial ischaemia and injury: the link is inflammation.General psychiatry · 2023Review
- Targeting the ferroptosis crosstalk: novel alternative strategies for the treatment of major depressive disorder.General psychiatry · 2023Review
- Causal associations between major depressive disorder and COVID-19.General psychiatry · 2023Article
- Special issue for psychosomatic medicine.General psychiatry · 2022Article
- Impact of depression on the quality of sleep and immune functions in patients with coronary artery disease.General psychiatry · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The association between inflammation and major depressive disorder (MDD) remains poorly understood, given the heterogeneity of patients with MDD. Aims: We investigated inflammatory markers, such as interleukin (IL)-6, high-sensitivity C reactive protein (hsCRP) and tumour necrosis factor-α (TNF-α) in melancholic, atypical and anxious depression and explored whether baseline inflammatory protein levels could indicate prognosis. Methods: The sample consisted of participants (aged 18-55 years) from a previously reported multicentre randomised controlled trial with a parallel-group design registered with ClinicalTrials.gov, including melancholic (n=44), atypical (n=37) and anxious (n=44) patients with depression and healthy controls (HCs) (n=33). Subtypes of MDD were classified according to the 30-item Inventory of Depressive Symptomatology, Self-Rated Version and the 17-item Hamilton Depression Rating Scale. Blood levels of TNF-α, IL-6 and hsCRP were assessed using antibody array analysis. Results: Patients with MDD, classified according to melancholic, atypical and anxious depression subtypes, and HCs did not differ significantly in baseline TNF-α, IL-6 and hsCRP levels after adjustment. In patients with anxious depression, hsCRP levels increased significantly if they experienced no pain (adjusted (adj.) p=0.010) or mild to moderate pain (adj. p=0.038) compared with those with severe pain. However, the patients with anxious depression and severe pain showed a lower trend in hsCRP levels than patients with atypical depression who experienced severe pain (p=0.022; adj. p=0.155). Baseline TNF-α (adj. p=0.038) and IL-6 (adj. p=0.006) levels in patients in remission were significantly lower than those in patients with no remission among the participants with the atypical depression subtype at the eighth-week follow-up. Conclusions: This study provides evidence of differences in inflammatory proteins in patients with varied symptoms among melancholic, atypical and anxious depression subtypes. Further studies on the immunoinflammatory mechanism underlying different subtypes of depression are expected for improved individualised therapy. Trial registration number: NCT03219008.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.